Arabic Arabic English English French French German German

Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19

NovartisNovartis and Molecular Partners announced that Part A of the EMPATHY clinical trial(1) that compared single intravenous doses of ensovibep, a DARPin antiviral therapeutic candidate vs. placebo to treat COVID-19, met the primary endpoint of viral load reduction over eight days. The two secondary endpoints also showed clinically meaningful benefit over placebo – (1) composite endpoint of hospitalization and/or Emergency Room (ER) visits or death, and (2) time to sustained clinical recovery.

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Severity of menopause symptoms can affect a woman’s cognitive performance

Next Post

Survival rate of patients with relapsed ALL after hematopoietic cell transplantation has steadily increased

Related Posts